66 related articles for article (PubMed ID: 21110951)
21. Response of human rhabdomyosarcoma cell lines to retinoic acid: relationship with induction of differentiation and retinoic acid sensitivity.
Ricaud S; Vernus B; Bonnieu A
Exp Cell Res; 2005 Dec; 311(2):192-204. PubMed ID: 16236281
[TBL] [Abstract][Full Text] [Related]
22. Cooperative action of 1alpha,25-dihydroxyvitamin D3 and retinoic acid in NB4 acute promyelocytic leukemia cell differentiation is transcriptionally controlled.
Bastie JN; Balitrand N; Guillemot I; Chomienne C; Delva L
Exp Cell Res; 2005 Nov; 310(2):319-30. PubMed ID: 16181625
[TBL] [Abstract][Full Text] [Related]
23. Identification and characterization of retinoic acid receptor beta2 target genes in F9 teratocarcinoma cells.
Zhuang Y; Faria TN; Chambon P; Gudas LJ
Mol Cancer Res; 2003 Jun; 1(8):619-30. PubMed ID: 12805409
[TBL] [Abstract][Full Text] [Related]
24. CRABP1 and CRABP2 Protein Levels Correlate with Each Other but Do Not Correlate with Sensitivity of Breast Cancer Cells to Retinoic Acid.
Enikeev AD; Komelkov AV; Axelrod ME; Galetsky SA; Kuzmichev SA; Tchevkina EM
Biochemistry (Mosc); 2021 Feb; 86(2):217-229. PubMed ID: 33832420
[TBL] [Abstract][Full Text] [Related]
25. Synergistic activation of Arg1 gene by retinoic acid and IL-4 involves chromatin remodeling for transcription initiation and elongation coupling.
Lee B; Wu CY; Lin YW; Park SW; Wei LN
Nucleic Acids Res; 2016 Sep; 44(16):7568-79. PubMed ID: 27166374
[TBL] [Abstract][Full Text] [Related]
26. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR.
Schug TT; Berry DC; Toshkov IA; Cheng L; Nikitin AY; Noy N
Proc Natl Acad Sci U S A; 2008 May; 105(21):7546-51. PubMed ID: 18495924
[TBL] [Abstract][Full Text] [Related]
27. Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1.
Marqués N; Sesé M; Cánovas V; Valente F; Bermudo R; de Torres I; Fernández Y; Abasolo I; Fernández PL; Contreras H; Castellón E; Celià-Terrassa T; Méndez R; Ramón Y Cajal S; Thomson TM; Paciucci R
Oncogene; 2014 Feb; 33(9):1124-34. PubMed ID: 23455324
[TBL] [Abstract][Full Text] [Related]
28. PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle.
Santamaría A; Fernández PL; Farré X; Benedit P; Reventós J; Morote J; Paciucci R; Thomson TM
Am J Pathol; 2003 Mar; 162(3):897-905. PubMed ID: 12598323
[TBL] [Abstract][Full Text] [Related]
29. The Mediator complex subunit MED25 is targeted by the N-terminal transactivation domain of the PEA3 group members.
Verger A; Baert JL; Verreman K; Dewitte F; Ferreira E; Lens Z; de Launoit Y; Villeret V; Monté D
Nucleic Acids Res; 2013 May; 41(9):4847-59. PubMed ID: 23531547
[TBL] [Abstract][Full Text] [Related]
30. The role of prostate tumor overexpressed 1 in cancer progression.
Cánovas V; Lleonart M; Morote J; Paciucci R
Oncotarget; 2017 Feb; 8(7):12451-12471. PubMed ID: 28029646
[TBL] [Abstract][Full Text] [Related]
31. A novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells.
Maggio V; Cánovas V; Félix AJ; Gómez V; de Torres I; Semidey ME; Morote J; Noé V; Ciudad CJ; Paciucci R
Cancer Lett; 2019 Jun; 452():158-167. PubMed ID: 30922918
[TBL] [Abstract][Full Text] [Related]
32. A Lipopeptidomimetic of Transcriptional Activation Domains Selectively Disrupts the Coactivator Med25 Protein-Protein Interactions.
Pattelli ON; Valdivia EM; Beyersdorf MS; Regan CS; Rivas M; Hebert KA; Merajver SD; Cierpicki T; Mapp AK
Angew Chem Int Ed Engl; 2024 May; 63(21):e202400781. PubMed ID: 38527936
[TBL] [Abstract][Full Text] [Related]
33. Multivalent and Bidirectional Binding of Transcriptional Transactivation Domains to the MED25 Coactivator.
Jeffery HM; Weinzierl ROJ
Biomolecules; 2020 Aug; 10(9):. PubMed ID: 32825095
[TBL] [Abstract][Full Text] [Related]
34. Assessment of machine-learning predictions for the Mediator complex subunit MED25 ACID domain interactions with transactivation domains.
Monté D; Lens Z; Dewitte F; Villeret V; Verger A
FEBS Lett; 2024 Apr; 598(7):758-773. PubMed ID: 38436147
[TBL] [Abstract][Full Text] [Related]
35. First results of largest study of genomes and cancer treatments available.
Future Oncol; 2010 Sep; 6(9):1373. PubMed ID: 20919822
[No Abstract] [Full Text] [Related]
36. Norstictic Acid Is a Selective Allosteric Transcriptional Regulator.
Garlick JM; Sturlis SM; Bruno PA; Yates JA; Peiffer AL; Liu Y; Goo L; Bao L; De Salle SN; Tamayo-Castillo G; Brooks CL; Merajver SD; Mapp AK
J Am Chem Soc; 2021 Jun; 143(25):9297-9302. PubMed ID: 34137598
[TBL] [Abstract][Full Text] [Related]
37. Conservation of coactivator engagement mechanism enables small-molecule allosteric modulators.
Henderson AR; Henley MJ; Foster NJ; Peiffer AL; Beyersdorf MS; Stanford KD; Sturlis SM; Linhares BM; Hill ZB; Wells JA; Cierpicki T; Brooks CL; Fierke CA; Mapp AK
Proc Natl Acad Sci U S A; 2018 Sep; 115(36):8960-8965. PubMed ID: 30127017
[TBL] [Abstract][Full Text] [Related]
38. A lipopeptidomimetic of transcriptional activation domains selectively disrupts Med25 PPIs.
Pattelli ON; Valdivia EM; Beyersdorf MS; Regan CS; Rivas M; Merajver SD; Cierpicki T; Mapp AK
bioRxiv; 2023 Mar; ():. PubMed ID: 36993479
[TBL] [Abstract][Full Text] [Related]
39. [Genetic and transcriptional evolution alters cancer cell line drug response].
Pourquier P; Azzi J
Bull Cancer; 2019 Jan; 106(1):9-10. PubMed ID: 30595222
[No Abstract] [Full Text] [Related]
40. SGK2, 14-3-3, and HUWE1 Cooperate to Control the Localization, Stability, and Function of the Oncoprotein PTOV1.
Pennington KL; McEwan CM; Woods J; Muir CM; Pramoda Sahankumari AG; Eastmond R; Balasooriya ER; Egbert CM; Kaur S; Heaton T; McCormack KK; Piccolo SR; Kurokawa M; Andersen JL
Mol Cancer Res; 2022 Feb; 20(2):231-243. PubMed ID: 34654719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
